Dr. Edward Kai-Hua Chow is Chief Scientific Officer of KYAN Technologies and a Fellow of the Royal Society of Chemistry. He was previously an Associate Professor at the National University of Singapore (NUS) in the Cancer Science Institute of Singapore and the Department of Pharmacology. He was also the Research Director for the Institute of Digital Medicine (WisDM) and Dept. of Pharmacology. He received his B.A. in Molecular and Cellular Biology from the UC Berkeley and his Ph.D. at UCLA. Prior to joining NUS, Dr. Chow was an American Cancer Society Postdoctoral Fellow under the guidance of Prof. J. Michael Bishop (1989 Nobel Prize in Physiology or Medicine) at UCSF. His research has focused on understanding how to treat specific oncology patients or patient subtypes through applying engineering-based analytics towards personalised and precision drug combination design. He has published over 90 peer-reviewed papers with more than 11,000 citations. More importantly, his research has been commercially implemented in the clinic to provide better treatment solutions for cancer patients.